SCIENTISTS have observed promising results in targeting the deadliest form of brain cancer with a type of immunotherapy.

Researchers at King’s College London and McMaster University in Canada reveal their findings today that indicate CAR-T cell therapy could be used to treat glioblastoma.

Patients with this type of brain cancer typically only live for 12 to 18 months after they are diagnosed.

Now routinely offered on the NHS, CAR-T immunotherapy teaches the body’s immune system to recognise and attack deadly cells.

Experts said their recent lab findings showed CAR-T eliminated tumours and suggested long-term disease-free survival.

They said that previous approaches have focused on killing cancer cells.

But lead author Professor Sheila Singh said this form of brain cancer is “not made up of cancer cells alone.A large portion of the tumour consists of immune cells called macrophages.

“Our approach targets both the tumour and the environment that allows it to thrive.”